Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.

Tenapanor proven safe, effective in treatment of IBS with constipation

16 Feb 2020

Treatment with tenapanor 50 mg twice daily (bid) results in improvement of constipation-predominant irritable bowel syndrome (IBS-C) symptoms and is generally well tolerated, a phase III study has shown.

A total of 629 patients with IBS-C were randomized to receive tenapanor 50 mg bid or placebo bid for 12 weeks, followed by a 4-week randomized withdrawal period. Of these, 606 (96.3 percent; mean age, 45 years; 81.4 percent women) were included in the intention-to-treat analysis set (tenapanor: n=307; placebo: n=299) and 533 (84.7 percent) completed the 12-week treatment period.

Significantly more patients treated with tenapanor vs placebo met the primary endpoint of a reduction in average weekly worst abdominal pain of ≥30.0 percent and an increase of ≥1 complete spontaneous bowel movement from baseline, both in the same week, for ≥6 weeks of the 12-week treatment period (27.0 percent vs 18.7 percent; p=0.020).

Tenapanor therapy also led to improvements in abdominal symptoms and global symptoms of IBS compared with placebo (p<0.05).

The most frequently reported adverse event was diarrhoea, which resulted in treatment cessation in 6.5 percent of patients receiving tenapanor and 0.7 percent of those treated with placebo during the 12-week treatment period.

In a previous study, tenapanor 50 mg bid was found to significantly increase stool frequency, as well as reduce abdominal symptoms in patients with IBS-C. [Am J Gastroenterol 2017;112:763-774]

 “Tenapanor is a first-in-class, minimally absorbed, small-molecule inhibitor of the gastrointestinal sodium/hydrogen exchanger isoform 3,” the investigators noted.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 27 Mar 2020
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 31 Mar 2020
Treatment with hydroxychloroquine appears to significantly reduce viral load in patients with the novel coronavirus disease (COVID-19), with its beneficial effects reinforced by adding azithromycin, results of a recent study have shown.
Elvira Manzano, 22 Nov 2017
A blood pressure (BP) reading of 130/80 mm Hg or higher is the ‘new high’ in the latest AHA/ACC* hypertension guidelines, a threshold that is tighter than the JNC 7** cutpoint of 140/90 mm Hg for stage 1 hypertension in the general population. The change will mean more patients being labelled with hypertension.
Audrey Abella, 27 Mar 2020
The angiotensin receptor blocker (ARB) losartan did not improve inflammation, T-cell immune recovery, or fibrotic activity among older persons living with HIV (PLHIV) and viral suppression, according to data presented at CROI 2020.